NCT00100841

Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: National Cancer Institute (NCI) · NIH
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab and cetuximab may kill more tumor cells. This phase II trial is studying how well giving combination chemotherapy together with bevacizumab and cetuximab works in treating patients with stage IV colorectal cancer that cannot be removed by surgery.

Detailed description

PRIMARY OBJECTIVES: I. To determine the safety, feasibility of administration, response rates and progression free survival among chemotherapy naïve patients with advanced colorectal cancer treated with FOLFOX6 plus bevacizumab and cetuximab (FBC). II. To determine the survival of patients with advanced colorectal cancer treated with FBC. III. To determine the safety of the current regimen in selected patients who have had prior MoAb therapy. OUTLINE: This is a multicenter study. Patients receive cetuximab IV over 60-120 minutes on day 1 in weeks 1-8. Patients also receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 48 hours on days 1 and 2 of weeks 1, 3, 5, and 7. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed for survival. PROJECTED ACCRUAL: A total of 40-67 patients will be accrued for this study.

Conditions

• Adenocarcinoma of the Rectum
• Mucinous Adenocarcinoma of the Colon
• Recurrent Colon Cancer
• Recurrent Rectal Cancer
• Signet Ring Adenocarcinoma of the Colon
• Stage IV Colon Cancer
• Stage IV Rectal Cancer

Interventions

Type	Name	Description
BIOLOGICAL	cetuximab	Given IV
BIOLOGICAL	bevacizumab	Given IV
DRUG	oxaliplatin	Given IV
DRUG	leucovorin calcium	Given IV
DRUG	fluorouracil	Given IV

Timeline

• Start date: 2004-11-01
• Primary completion: 2011-07-01
• Completion: 2011-07-01
• First posted: 2005-01-07
• Last updated: 2015-07-27
• Results posted: 2015-07-27

Locations

1 site across 1 country: United States